Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

• Status: Recruiting
• Trial end date: 2028-06-30

Summary

This randomized phase III trial studies how well imatinib mesylate and combination chemotherapy work in treating patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving imatinib mesylate and combination chemotherapy may work better in treating patients with Philadelphia chromosome positive acute lymphoblastic leukemia.

• Phase: Phase 3

Details

• Lead Sponsor: Children's Oncology Group
• Collaborators: EsPhALL network I-BFM Study Group; National Cancer Institute (NCI)
• Treatments: 2-Aminopurine; 6-Mercaptopurine; Asparaginase; Azathioprine; BB 1101; Calcium; Calcium, Dietary; Cortisol succinate; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate; Dexrazoxane; Doxorubicin; Etoposide; Etoposide phosphate; Folic Acid; Hydrocortisone; Hydrocortisone 17-butyrate 21-propionate; Hydrocortisone acetate; Hydrocortisone hemisuccinate; Ifosfamide; Imatinib Mesylate; Isophosphamide mustard; Lenograstim; Leucovorin; Levoleucovorin; Liposomal doxorubicin; Mercaptopurine; Mesna; Methotrexate; Methylprednisolone; Methylprednisolone Acetate; Methylprednisolone Hemisuccinate; Pegaspargase; Podophyllotoxin; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate; Razoxane; Thioguanine; Vincristine